Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending September 22, 2003. The report serves as a notification of changes in directors' interests in the company's Ordinary Shares and American Depositary Receipts (ADRs), rather than a comprehensive financial performance report.
Key Financial Metrics
The filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on equity transactions related to employee benefit plans.
Material Changes
The filing details specific movements in shareholdings within employee trusts and retirement plans:
- Employee Share Option Plan 1991: The GSK Trust transferred a total of 41,108 Ordinary Shares to participants across three transactions on September 17 and 18, 2003 (3,004 shares, 20,616 shares, and 17,488 shares respectively).
- US Retirement Savings Plan: The number of Ordinary Share ADRs held by the fund decreased from 18,949,156 to 18,882,865 on September 18, 2003, due to fund movements. The average price for this movement was $42.59.
Management Commentary and Risks
Management notes that Directors Dr. J-P Garnier and Mr. J D Coombe hold interests in the GSK Trust shares in the same capacity as other employees. Similarly, Director Dr. J P Garnier has a potential interest in the US Retirement Savings Plan shares. The filing does not contain specific guidance, outlook, or discussion of operational risks beyond the standard disclosure of director interests.
Investor Verification Checklist
- Verify the total number of shares transferred to the SmithKline Beecham Employee Share Option Plan 1991 (41,108 shares).
- Confirm the reduction in ADR holdings within the US Retirement Savings Plan (66,291 shares).
- Note the average transaction price of $42.59 for the ADR movement.
- Identify the specific directors with disclosed interests: Dr. J-P Garnier and Mr. J D Coombe.